Demographic data, presenting symptoms and CSF/serum data of patients with GABABR and AMPAR abs
| Number | Sex; age | Limbic symptoms | Extralimbic symptoms | Abs | Ab proving study | Earliest CSF | Other abs | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Latency (days) | Serum titre | CSF titre | Ab index | Latency (days) | Cells/µL | OCB | Intrathecal IgG synthesis | ||||||
| 1 | M; 51 | Memory deficits | Apraxia, psychotic symptoms | GABABR | 8 | 100 | 32 | 57.9 | 8 | 78 | + | + | − |
| 2 | M; 65 | Seizures, memory deficits | Cognitive decline | GABABR | 0 | 100 | ND | ND | 26 | 10 | + | + | − |
| 3 | M; 72 | Seizures, memory deficits, confusion, | Cognitive decline, gait and stance difficulties | GABABR | 9 | 500 | 250 | 100 | 2 | 47 | + | + | Hu (S+CSF) |
| 4 | M; 75 | Seizures, confusion, psychomotor agitation | Catatonia, aphasia, nystagm, oculomotor disorder | GABABR | 31 | 50 000 | ND | ND | 11 | 23 | + | + | − |
| 5 | F; 60 | Seizures (SE) | Psychosyndrome | GABABR | 8 | Positive* | 1000 | ND | 0 | 13 | + | ND | − |
| 6 | F; 74 | Memory deficits, confusion | Gait difficulties, psychomotor agitation | GABABR | 4 | 50 000 | 375 | 2.6 | 4 | 4 | − | − | SOX-1 (S+CSF) |
| 7 | M; 71 | Seizures | GABABR | 266 | 2000 | ND | ND | 7 | ND | + | + | − | |
| 8 | M; 62 | Seizures, confusion | Change of personality | GABABR | 8 | 2000 | 750 | 84.6 | 0 | 39 | + | + | SOX-1 (S) |
| 9 | M; 69 | Seizures (SE), memory deficits, confusion | Apraxia, aphasia, intention tremor | GABABR | 33 | 1000 | 250 | 86.2 | 33 | 11 | + | − | − |
| 10 | M; 70 | Seizures, memory deficits, | Word-finding difficulties | GABABR | 4 | 1000 | 200 | 69.0 | 4 | 2 | + | − | SOX-1 (S+CSF) |
| 11 | M; 61 | Memory deficits (multi-phase) | AMPAR2 (GLU-R2) | 9 | 32 | ND | ND | 9 | <3 | ND | − | − | |
| 12 | M; 62 | Memory deficits (multi-phase) | Psychosyndrome | AMPAR2 (GLU-R2) | 4 | 4000 | 16 | 0.57 | 4 | 16 | ND | − BBB disruption | − |
| 13 | F; 61 | Memory deficits (multi-phase) | Psychosyndrome | AMPAR2 (GLU-R2) | 128 | 16 000 | ND | ND | 0 | 0 | − | − | |
*nNo sufficient material for titration.
ab, Antibody; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; BBB, blood–brain barrier; CSF, cerebrospinal fluid; F, female; GABABR, γ-aminobutyric acid B receptor; Glu-R2, glutamate receptor 2; M, male; ND, not done; OCB, oligoclonal bands; S, serum; SE, status epilepticus.